Dergiler / Turkish Journal of Hematology / 2020 / Cilt: 37 - Sayı: 2

Endocrine and Metabolic Disorders after Hematopoietic Cell Transplantation

Hematopoietik Hücre Transplantasyonu sonrası Endokrin ve Metabolik Bozukluklar

Sayfa
111–115
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The aim of this article is todescribe metabolic dysfunctions occurring in patients who underwentallogeneic cell transplantation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Chemotherapy treatment and autologous and allogeneic celltransplantations are often complicated by the onset of metabolicand endocrine disorders.
📊
Temel Bulgular & Veri:Autoimmune disorders, metabolic diseases,and hormonal dysfunctions are some of the endocrine complicationsobserved during or after treatment with immunotherapy (mostlynovel agents) and/or chemotherapy conditioning for transplantation.Although successful treatment of the underlying hematologicalcondition often improves the dysfunction, endocrinopathies canhave an impact on prognosis and are associated with poor survival;therefore, it is important to detect and treat them as early as possible.An increased incidence of cardiovascular diseases and metabolicsyndrome has been observed after transplantation mostly in longterm survivors.
💡
Sonuç & Katkı:The aim of this article is todescribe metabolic dysfunctions occurring in patients who underwentallogeneic cell transplantation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Chemotherapy treatment and autologous and allogeneic celltransplantations are often complicated by the onset of metabolicand endocrine disorders. Autoimmune disorders, metabolic diseases,and hormonal dysfunctions are some of the endocrine complicationsobserved during or after treatment with immunotherapy (mostlynovel agents) and/or chemotherapy conditioning for transplantation.Although successful treatment of the underlying hematologicalcondition often improves the dysfunction, endocrinopathies canhave an impact on prognosis and are associated with poor survival;therefore, it is important to detect and treat them as early as possible.An increased incidence of cardiovascular diseases and metabolicsyndrome has been observed after transplantation mostly in longterm survivors. In addition, chemotherapy and radiation along withthe prolonged use of corticosteroids can contribute to the onsetof thyroid and gonadal dysfunctions. The aim of this article is todescribe metabolic dysfunctions occurring in patients who underwentallogeneic cell transplantation.

Abstract

Kemoterapi tedavisi ve otolog ve allojeneik hücre transplantasyonları, metabolik ve endokrin bozuklukların başlaması ile sıklıkla komplike olmaktadır. Otoimmün bozukluklar, metabolik hastalıklar, ve hormonal disfonksiyonlar immünoterapi (çoğunlukla yeni ajanlar) ve/veya transplantasyon için uygulanan hazırlama rejimi sırasında veya sonrasında gözlenen bazı endokrin komplikasyonlardır. Altta yatan hematolojik durumun başarılı tedavisi endokrin disfonksiyonu sıklıkla iyileştirmekle birlikte, endokrinopatilerin prognoz üzerine etkisi olabilir ve kısa yaşam süresi ile ilişkilidir; bu nedenle mümkün olduğu kadar erken saptanmaları ve tedavi edilmeleri önemlidir. Çoğunlukla uzun dönem sağkalan hastalarda transplantasyon sonrası kardiyovasküler hastalıklar ve metabolik sendromun insidansında artma gözlenmektedir. Ek olarak, kortikosteroidlerin uzun süreli kullanımı ile birlikte kemoterapi ve radyoterapi tiroid ve gonadal bozuklukların başlamasına katkıda bulunabilir. Bu yazının amacı allojeneik kök hücre transplantasyonu uygulanan hastalarda metabolik bozuklukların anlatılmasıdır.

🔖

Bu Makaleye Atıf Yap

PAVİGLİANİTİ, A. (2020). Endocrine and Metabolic Disorders after Hematopoietic Cell Transplantation. Turkish Journal of Hematology, Cilt: 37 - Sayı: 2, 111–115. https://ajindex.com/articles/413283

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322-334
  2. Lee JH, Choi SJ, Lee JH, Kim SE, Seol M, Lee YS, Lee JS, Kim WK, Lee KH. Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005;35:63-69
  3. Ho AY, Mijovic A, Pagliuca A, Mufti GJ. Idiopathic hyperammonaemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplant 1997;20:1007-1008
  4. Healy SJ, Dungan KM. Hyperglycemia in patients with hematologic malignancies. Curr Diab Rep 2015;15:8
  5. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-474
  6. Smith LK, Cidlowski JA. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res 2010;182:1-30
  7. Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1023-1030
  8. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178
  9. Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 2019;98:19-28
  10. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-2494
  11. American Society of Clinical Oncology; Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947
  12. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014;722:197- 202
  13. Griffith ML, Jagasia M, Jagasia SM. Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract 2010;16:699-706
  14. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N; DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-1514
  15. Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem c